Fundz

Cnd Life Sciences, Inc. reported raising $825,000 in an initial SEC Form D filing, from an offering of $2.5 Million

PRIVATEJan 20, 2021$825K of $2.5M raised

Amount Raised

$825,000

$825,000 sold, per SEC Form D (first sale Jan 20, 2021)

Round Type

Seed

ScottsdaleBiotechnology

Who else raised in Biotechnology around the same time

Companies in the same sectors as CND Life Sciences that raised within 45 days of this round, from Fundz verified event records.

  • Sycamore Biopharma raised an undisclosed amount on March 5, 2021.
  • Immunoprofile raised $1.2M on March 5, 2021.
  • Variantyx raised $16M on March 5, 2021.
  • OnKure Therapeutics raised $29M on March 5, 2021.
  • Caribou raised $115M on March 5, 2021.
  • Sarcio raised $785K (Seed) on March 5, 2021.

Who to call at CND Life Sciences, and when

A new round usually means CND Life Sciences is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day CND Life Sciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at CND Life Sciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at CND Life Sciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

CND Life Sciences

Location

9165 E. DEL CAMINO DRIVE

Scottsdale, Arizona, United States

About

CND Life Sciences is dedicated to supporting the care of patients suffering from neurodegenerative diseases and other conditions. Operating a CLIA-certified laboratory in Scottsdale, AZ, CND launched the Syn-One Test® as the first commercially available test to detect, visualize, and quantify the presence of misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid in the confirmation of a synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF). Through analysis of three small in-office skin biopsies provided by a referring physician, CND offers a convenient, accurate, minimally invasive alternative to aid in the diagnosis of neurodegenerative diseases. The company has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment CND Life Sciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

3 contacts
Verified contactsRick M., Executive Officer, DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for CND Life Sciences's next move

See what Strategic adds

CND Life Sciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.